News · Brain & Mental Health
Angiotensin receptor blockers tracked 8% less dementia than calcium channel blockers
If a blood pressure drug protects the brain, the obvious explanation is the blood pressure. Emulating a trial across 52,019 older Japanese adults, one class tracked less dementia than another despite both reaching the same pressure.
- One class of blood pressure drug tracked about 8% less dementia than another.
- Both groups reached the same blood pressure, so that is not the explanation.
- The gap was widest for vascular dementia, but rested on only 129 cases.
- Alzheimer's disease on its own showed no clear difference.
- 52,019 older adults in Japanese records, in an analysis built to imitate a trial.
Lowering blood pressure protects the brain. That much is settled, and it is the reason treating hypertension appears on every list of things that reduce dementia risk.
The unsettled question is whether the particular drug matters once the pressure is down. Writing in Alzheimer’s & Dementia, researchers built an analysis to test it: among 52,019 eligible new users aged 65 and over in Japan, those starting an angiotensin receptor blocker were compared against those starting a calcium channel blocker.
Angiotensin receptor blocker initiation was associated with lower all-cause dementia risk, by about 8%. And it happened with similar achieved blood pressure in both groups.
Why that second detail carries the piece
Two drugs that lower blood pressure by the same amount should, on the standard story, protect the brain by the same amount. The pressure is supposed to be the mechanism.
Here they did not. Both groups arrived at similar readings and one still had less dementia, which means either something other than pressure is involved or the difference is an artifact of who received which prescription.
That is the whole interest of the study, and it is why the design matters as much as the result.
What a target trial emulation does
Comparing people on drug A with people on drug B is normally hopeless, because doctors choose. The choice encodes everything they know about the patient, and much of it also predicts dementia.
A target trial emulation attacks that by writing the protocol first. Eligibility is defined, the moment of treatment initiation is fixed, follow-up starts there, and the analysis then finds people in the records who meet those conditions. It rules out several specific errors, notably the one where a treatment appears protective because people had to survive long enough to receive it.
What it cannot do is randomize. The prescriber’s judgment is still in the data, and no protocol written afterwards removes it.
Where the effect was and was not
The overall figure is modest. Across 3,524 dementia events, the reduction was around 8%, with an interval that stops just short of no effect at all.
Underneath it the subtypes diverged. For Alzheimer’s disease, on 2,231 events, no clear difference emerged. The association was stronger for vascular dementia, at roughly 38% lower, and that is the number to be careful with: it rests on 129 events split between two groups.
A 38% reduction built on 129 cases is not a firm estimate. Reclassify a handful of diagnoses, which happens routinely in dementia coding, and it moves.
The direction that makes biological sense
Unusually for this kind of finding, the pattern fits the proposed mechanism rather than contradicting it.
Angiotensin receptor blockers work by blocking one receptor for angiotensin, leaving the hormone circulating to act elsewhere. Calcium channel blockers relax vessel walls by an entirely different route. If the benefit here is real, the leading explanation involves that difference in how the angiotensin system is left, rather than the pressure result both achieve.
Vascular dementia being the subtype that moved is also coherent: it is the form built out of damage to small blood vessels, which is where a difference between two vascular drugs would be expected to show up first.
Coherence is not proof. It does raise the value of running the trial.
What would settle it
A randomized comparison of the two classes with dementia as a pre-specified outcome, in people who need treatment either way. It has not been done, because it would need many thousands of people followed for a decade, and neither drug is under patent.
That absence is why the question keeps being asked of databases instead, and why every answer arrives with the same caveat attached.
What it means for anyone taking these drugs
Nothing immediate. The blood pressure medicine that suits a person is the one that controls their pressure without causing problems, and swapping on the strength of an 8% difference in an observational analysis would be a poor trade against the reasons the current drug was chosen.
Its value is upstream of the clinic. Two drug classes, one blood pressure, different dementia rates is a specific, checkable claim, and it is the kind of claim that eventually justifies someone funding the trial that answers it properly.
People also ask
What did the study find?
Among 52,019 new users followed a median 3.6 years, angiotensin receptor blocker initiation was associated with lower all-cause dementia risk than calcium channel blocker initiation (HR 0.916; 95% CI 0.852-0.985), with similar achieved blood pressure. For Alzheimer's disease the association was not statistically significant (HR 0.930; 95% CI 0.849-1.018). For vascular dementia it was stronger (HR 0.617; 95% CI 0.409-0.930) on 129 events.
What is a target trial emulation?
An analysis of existing records designed to imitate the trial nobody ran: eligibility, treatment start and follow-up are specified in advance as a trial protocol would, then applied to the data. It removes several classic biases and it does not create random assignment.
Why does the blood pressure detail matter so much?
Because it removes the obvious explanation. If the two groups had ended up at different pressures, the dementia difference would simply be the pressure. Both reached similar levels, so any real effect would have to come from something else the drugs do.
How reliable is the vascular dementia result?
It is the largest effect and the weakest number. It rests on 129 events across both groups, which is few enough that the estimate could move substantially with a handful of reclassified diagnoses.
Is 8% worth anything?
For one person, very little. Across the very large number of people taking these drugs it would matter, which is the usual shape of a population-level finding. It is also close enough to no effect that residual confounding could account for it.
Should anyone switch drugs?
No. Blood pressure medicines are chosen on how well they control pressure in a particular person alongside kidney function, heart history and side effects, none of which this addresses. This is general information rather than medical advice.
Has this been tested directly?
Not as a randomized comparison with dementia as the outcome. That trial would take years and has not been funded, which is why analyses like this one keep being run on existing records.